GLP-1 Medications — Complete FAQ

GLP-1 (glucagon-like peptide-1) medications are a class of injectable drugs that mimic a hormone naturally released by your gut after eating. They include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). They reduce appetite, improve blood sugar control, slow gastric emptying, and produce significant weight loss. Tirzepatide also activates GIP receptors (dual agonist), producing superior results to GLP-1-only drugs.

GLP-1 medications act on appetite centers in the brain (hypothalamus and brainstem) to reduce hunger signals and "food noise" — the constant mental preoccupation with food. They also slow gastric emptying so you feel full longer after meals, and reduce hedonic eating cravings. The result is significantly reduced caloric intake without consciously dieting.

No — GLP-1 medications are completely different from insulin. Insulin directly lowers blood sugar by facilitating glucose uptake. GLP-1 medications stimulate your own pancreas to release insulin only when blood sugar is elevated (glucose-dependent), and have multiple other mechanisms including appetite suppression and weight loss. GLP-1 medications have much lower hypoglycemia risk than insulin.

GLP-1 medications are intended for long-term, chronic use — similar to blood pressure or cholesterol medications. Most people need to stay on them indefinitely to maintain weight loss results. Studies show approximately two-thirds of lost weight is regained within 1–2 years of stopping. Obesity and type 2 diabetes are chronic conditions, and GLP-1 therapy is a long-term treatment.

Yes — all GLP-1 medications require a prescription from a licensed healthcare provider. They can be prescribed by primary care physicians, endocrinologists, obesity medicine specialists, and via telehealth platforms. You cannot legally obtain these medications without a valid prescription in the United States.

Both contain semaglutide, but Wegovy's max dose is 2.4mg vs Ozempic's 2mg. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for weight management and cardiovascular risk reduction. Wegovy uses a 5-step escalation vs 4 steps for Ozempic. Wegovy produces slightly more weight loss due to the higher dose (~15% vs ~11%). See our full Ozempic Guide and Wegovy Guide.

Mounjaro and Zepbound are identical medications — both contain tirzepatide at the same doses. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management and sleep apnea. The clinical difference is which diagnosis code your insurance uses. Dosing, efficacy, and side effects are identical.

Mounjaro/Zepbound (tirzepatide) produces significantly more weight loss — 20–21% vs 15% for Wegovy in clinical trials. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 47% more weight loss than semaglutide at maximum doses. Tirzepatide also causes less nausea. See our full comparison.

Yes. Wegovy and Zepbound are FDA-approved for weight management in adults without diabetes who have a BMI of 30+ or 27+ with a weight-related condition. Ozempic is sometimes prescribed off-label for weight loss in people without diabetes. Mounjaro is only FDA-approved for diabetes but can also be used off-label.

Yes — Rybelsus is an oral semaglutide tablet approved for type 2 diabetes. It is taken daily on an empty stomach with a small amount of water and must be taken 30 minutes before food or other medications. It is less potent than injectable semaglutide (Ozempic/Wegovy) but is an option for people who prefer to avoid injections. There is no oral tirzepatide available yet.

Ozempic, Wegovy, Mounjaro, Zepbound, and Trulicity are all injected once weekly — same day each week. Saxenda (liraglutide) is the exception — it is injected daily. Use our Dose Schedule Builder to generate your personalized injection calendar.

No — you do not have to reach the maximum dose. Many patients achieve excellent weight loss and blood sugar results at intermediate doses and stay there permanently. Your doctor may keep you at a lower dose if you are losing weight satisfactorily and tolerating it well. Reaching maximum dose is not a requirement for treatment success.

For semaglutide (Ozempic/Wegovy): if fewer than 5 days have passed, take it now and reset your weekly schedule. If more than 5 days, skip and resume on your regular day. For tirzepatide (Mounjaro/Zepbound): the window is 4 days. Never take a double dose. See our full Missed Dose Guide.

Yes — you can change your weekly injection day as long as you maintain at least 2 days (48 hours) between your last injection and the new day. Pick your new day and inject on that day, then continue weekly from there. Update your reminders accordingly.

Maximum therapeutic effect is reached after completing the full dose escalation — approximately 12 weeks for Ozempic, 16 weeks for Wegovy, and 20 weeks for Mounjaro/Zepbound at maximum dose. Most people notice appetite suppression within the first 1–2 weeks even at the initiation dose.

Clinical trial averages: Ozempic 2mg (~11%), Wegovy 2.4mg (~15%), Zepbound 15mg (~21%). Real-world results are typically 20–30% lower than trial averages due to less intensive support and variable adherence. Individual results vary significantly — some lose much more, some less. Use our Weight Loss Predictor for a personalized estimate.

Most people lose 2–5 lbs in the first month during dose escalation, then 0.5–1.5 lbs per week at therapeutic doses. Weight loss is fastest in months 3–9 and slows as you approach your body's new equilibrium, typically plateauing around months 12–18. See our Weight Loss Results guide for month-by-month data.

Possible reasons: you may be at an initiation dose (not yet therapeutic), you may have untreated thyroid disease or other medical conditions reducing response, certain medications counteract weight loss, you may be a genetic non-responder (~10–15% of patients), or calorie intake may not be sufficiently reduced. Use our Plateau Calculator to diagnose your specific situation.

Yes — significantly. GLP-1 medications suppress appetite but don't direct the body to lose fat vs muscle. People who eat high-protein diets and do resistance training lose far more fat and preserve more muscle than those who don't. The STEP 3 trial (Wegovy + intensive lifestyle) showed 16% weight loss vs 14.9% without — modest but meaningful improvement that compounds over time.

The most common are nausea (15–44%), diarrhea (17–30%), vomiting (9–24%), constipation (11–24%), and abdominal pain. These are worst during dose escalation and typically improve significantly by weeks 8–12. Tirzepatide causes significantly less nausea than semaglutide. See our full Side Effects Guide.

Inject before bedtime to sleep through peak nausea, eat smaller and slower meals, avoid fatty and very sweet foods especially on injection day, stay well hydrated, and stay upright for at least an hour after eating. Ginger tea or chews can help. Ask your doctor about ondansetron (Zofran) for severe cases.

"Ozempic face" — facial volume loss and sagging — is real but is a consequence of rapid weight loss in general, not a direct drug effect. It is more noticeable in older patients and those losing large amounts of weight quickly. It is not medically dangerous. Prevention strategies include slower weight loss, adequate protein intake, and sun protection.

Serious but rare risks include pancreatitis, gallbladder disease, diabetic retinopathy changes, and kidney injury from dehydration. All GLP-1 medications carry an FDA boxed warning for potential thyroid C-cell tumors (seen in rodent studies — not confirmed in humans). Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN 2.

For Wegovy and Zepbound: adults with BMI ≥30 (obesity) OR BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, or sleep apnea). Check your eligibility instantly with our BMI Eligibility Calculator.

Wegovy is FDA-approved for adolescents aged 12 and older for weight management. Saxenda is approved for adolescents 12+. Ozempic, Mounjaro, and Zepbound are currently approved for adults only (18+). Pediatric use requires specialist supervision.

No — GLP-1 medications are contraindicated during pregnancy. They should be stopped at least 2 months before attempting to conceive. If you become pregnant while on a GLP-1 medication, stop immediately and contact your healthcare provider. Animal studies have shown fetal harm at high doses.

GLP-1 medications can interact with several drugs. They slow gastric emptying, which delays absorption of oral medications — particularly oral contraceptives (take at least 1 hour before injection day), levothyroxine (thyroid medication), and warfarin. They enhance the blood sugar-lowering effects of insulin and sulfonylureas, increasing hypoglycemia risk. Always disclose all medications to your prescriber.

List prices: Ozempic ~$935/month, Wegovy ~$1,349/month, Mounjaro ~$1,023/month, Zepbound pen ~$1,060/month. Zepbound vials via LillyDirect: $349–$549/month for self-pay patients. With insurance and manufacturer savings cards, costs can drop to $0–$200/month. See our full Cost & Insurance Guide.

Coverage varies. Ozempic/Mounjaro are more commonly covered for type 2 diabetes. Wegovy/Zepbound are more often covered for obesity diagnoses. Prior authorization is almost always required. Manufacturer savings cards can reduce costs to as low as $0–$25/month for eligible commercially insured patients.

For self-pay patients, Zepbound single-dose vials through LillyDirect at $349–$549/month is currently the most affordable FDA-approved option — and also produces the most weight loss. For insured patients, all major GLP-1 drugs can be brought to $25–$200/month with the right savings card and insurance strategy.

Prioritize lean protein first at every meal (1.2–1.6g per kg of body weight daily), non-starchy vegetables, and small portions of whole grains. Avoid high-fat fried foods, sugary drinks, alcohol, and large portions. Eating protein first ensures you meet your protein target before fullness cuts the meal short. See our Foods to Avoid and Protein Calculator.

Exercise is not required but strongly recommended. Without resistance training, 25–40% of GLP-1 weight loss can come from muscle rather than fat — reducing your metabolic rate and increasing plateau and regain risk. Even 2 sessions per week of basic resistance training can ensure the vast majority of weight lost comes from fat. See our Muscle Loss Guide.

Alcohol is not recommended. It worsens nausea, increases hypoglycemia risk in diabetic patients, provides empty calories, and may cause unexpectedly stronger intoxication due to slowed gastric emptying. If you choose to drink, limit strictly to 1 drink, always eat food first, and be aware your tolerance may be lower than before.

When you stop, appetite returns to pre-treatment levels within 4–8 weeks and most people regain weight. Studies show approximately two-thirds of lost weight is regained within 1–2 years of stopping. Blood sugar control also reverts in diabetic patients. These medications treat obesity and diabetes as chronic conditions and are designed for long-term use.

Yes — most anesthesiology guidelines recommend stopping GLP-1 medications 1–2 weeks before elective surgery (up to 4 weeks for major procedures) due to delayed gastric emptying risk. Always confirm the specific timeline with your surgical and anesthesia team. See our Half-Life Calculator to understand your drug levels.

Yes — switching is common, particularly for people who plateaued or experienced excessive side effects. No washout period is required between GLP-1 medications. Your doctor will typically restart escalation from the beginning of the new drug's schedule to allow GI adaptation. Many patients who switched from semaglutide to tirzepatide report both better results and fewer side effects.